Abstract: Disclosed in the present disclosure are a potassium salt crystal form B of a phosphodiesterase type 5 inhibitor, and a preparation method and a use therefor. The structural formula of the phosphodiesterase type 5 inhibitor is as shown in a formula (I), and the X-ray powder diffraction (XRPD) pattern of the potassium salt crystal form B has characteristic peaks at the following 2? angles: 5.71°±0.2°, 8.23°±0.2°, 11.37°±0.2°, 13.22°±0.2°, 17.09°±0.2°, 21.56°±0.2°, 23.99°±0.2°, and 25.85°±0.2°. Further disclosed in the present disclosure is a use for the present crystal form potassium salt in preparing drugs for treating pulmonary hypertension, idiopathic pulmonary fibrosis, renal fibrosis, myocardial hypertrophy, or erectile dysfunction.

Abstract: A device and method for degassing an on-load tap-changer (OLTC) of a transformer for convenient on-site operation. The degassing device includes an OLTC. The OLTC is respectively connected with an oil suction pipe and an oil injection pipe. One end of the oil suction pipe extends to the inside bottom of the OLTC, and the other end of the oil suction pipe extends to the outside of the OLTC to connect with an oil suction and degassing device. One end of the oil injection pipe extends to an upper part inside the OLTC, and the other end of the oil injection pipe extends to the outside of the OLTC to connect with a vacuum oil injection device. The present disclosure has the advantages of convenient on-site operation, excellent degassing effect, simple structure and convenient installation, reduces degassing time and manpower and investment in maintenance, and improves degassing quality.

Abstract: The embodiments disclosed herein provide a peptoid, which is a compound of Formula I or a stereoisomer, a mixture of stereoisomers, or a pharmaceutically acceptable salt thereof. N—R4, N—R3, N—R2, and N—R1 in Formula I are respectively. The peptoid has a strong binding ability with EGFR protein. It can be used not only for targeted treatment of diseases associated with EGFR protein, but also for imaging detection or prognosis monitoring of diseases associated with EGFR protein.

Abstract: A peptoid compound, a nanometer carrier, a pharmaceutical composition, and use of the pharmaceutical composition in manufacture of a medicament for treatment of a disease related to human epidermal growth factor receptor 1 (EGFR). The peptoid compound includes: cysteine (Cys) subunit, 1,4-butanediamine (Nlys) subunit, piperonylamine subunit, ?-alanine subunit and 1-naphthylamine subunit. The peptoid compound has high affinity and targeting effect to the EGFR protein, and high selectivity, and meanwhile has high medicament loading efficiency, no toxicity, and high safety.

Abstract: A microfluidic particle sorting apparatus for capturing targets from fluid containing the targets is disclosed. The apparatus includes an inlet for receiving the fluid; a sorting chamber allowing the fluid to flow through; a first outlet for discharging the fluid after flowing through the sorting chamber; a capturing structure for capturing the cells, wherein the capturing structure is upstream of the first outlet, and includes obstacles in an array, each extending through the sorting chamber in a lateral direction with respect to a fluid flow of the fluid; and a second outlet upstream of the capturing structure comprising a plurality of openings; wherein a gap between two adjacent obstacles is equal to or greater than each opening of the second outlet.

Abstract: Provided is application of genetically engineered bacteria VNP20009-M in preparation of drugs for preventing and treating malignant sarcoma.

Abstract: Provided is use of a genetically engineered bacterium of attenuated Salmonella typhimurium for treating liver cancer. The bacterium is attenuated Salmonella typhimurium VNP20009 carrying a plasmid cloned with a methioninase gene. Also provided is a construction method of the bacterium.

Abstract: The present disclosure provides a data reading circuit and a storage unit. The data reading circuit includes a being read unit connected to a voltage stabilizing unit and configured to store data. The voltage stabilizing unit is configured to stabilize and output a current from the being read unit to a first amplifying unit. The first amplifying unit is configured to amplify and output the current from the being read unit to a comparing unit. A reference unit is connected to a second amplifying unit, to output a reference current to the second amplifying unit. The second amplifying unit is configured to amplify and output the reference current to the comparing unit. The comparing unit is configured to compare a comparing point voltage, that is based on the amplified current of the being read unit and the amplified reference current, with a reference voltage and to output comparison results.

Abstract: A microfluidic particle sorting apparatus for capturing targets from fluid containing the targets is disclosed. The apparatus includes an inlet for receiving the fluid; a sorting chamber allowing the fluid to flow through; a first outlet for discharging the fluid after flowing through the sorting chamber; a capturing structure for capturing the cells, wherein the capturing structure is upstream of the first outlet, and includes obstacles in an array, each extending through the sorting chamber in a lateral direction with respect to a fluid flow of the fluid; and a second outlet upstream of the capturing structure comprising a plurality of openings; wherein a gap between two adjacent obstacles is equal to or greater than each opening of the second outlet.

Abstract: A reaction device for a detection chip and a reaction system are provided. The reaction device includes a chip carrier and an electrical signal control unit. The chip carrier is configured to place and fix the detection chip; and the electrical signal control unit is configured to apply an electrical signal to the detection chip so as to drive a heating electrode of the detection chip.

Abstract: Provided are a viral vector for treating autoimmune disease and diabetes and a construction method and an application thereof. The viral vector is a lentiviral expression plasmid or an adeno-associated viral expression plasmid cloned with mfat-1 gene, and the mfat-1 gene is as shown in SEQ ID NO: 1.

Abstract: A peptoid compound, a nanometer carrier, a pharmaceutical composition, and use of the pharmaceutical composition in manufacture of a medicament for treatment of a disease related to human epidermal growth factor receptor 1 (EGFR). The peptoid compound includes: cysteine (Cys) subunit, 1,4-butanediamine (Nlys) subunit, piperonylamine subunit, ?-alanine subunit and 1-naphthylamine subunit. The peptoid compound has high affinity and targeting effect to the EGFR protein, and high selectivity, and meanwhile has high medicament loading efficiency, no toxicity, and high safety.

Abstract: A detection chip, a using method for the same, and a reaction system. The detection chip includes a first substrate, a micro-cavity defining layer, and a heating electrode. The micro-cavity defining layer is on the first substrate and defines a plurality of micro-reaction chambers. The heating electrode is on the first substrate and is closer to the first substrate than the micro-cavity defining layer, and is configured to heat a plurality of micro-reaction chambers. The orthographic projection of the plurality of micro-reaction chambers on the first substrate is within the orthographic projection of the heating electrode on the first substrate.

Abstract: A detection chip, a method for operating a detection chip, and a reaction system are disclosed. The detection chip includes a first substrate, a micro-cavity defining layer, a hydrophilic layer, and a hydrophobic layer. The micro-cavity defining layer is on the first substrate and defines a plurality of micro-reaction chambers. Each of the plurality of micro-reaction chambers includes a reaction trap, and the reaction trap includes a sidewall and a bottom. The micro-cavity defining layer includes a spacing region between the plurality of micro-reaction chambers, and the spacing region includes a first region adjacent to the sidewall, and a second region non-adjacent to the sidewall. The hydrophilic layer covers the sidewall and the bottom of each of the plurality of micro-reaction chambers, and the hydrophobic layer covers the second region.

Abstract: A biological chip, a manufacturing method thereof, an operation method thereof, and a biological detection system are provided. The biological chip includes a base substrate and a plurality of working units. The plurality of the working units are arranged on the base substrate; each of the working units includes a working element configured to be in contact with a target substance; and the working element includes a metal electrode and an electric-field-controllable surface modification layer on a surface of the metal electrode.

Abstract: A peptoid compound, a manufacturing method of a peptoid compound, an oligomer, a pharmaceutical composition, use of the pharmaceutical composition in the preparation of a medicament for detecting or diagnosing a disease related to tyrosine kinase HER2, and a kit for identifying circulating tumor cells are provided, the peptoid compound includes: a cysteine (Cys) subunit, a butanediamine (Nlys) subunit, a 3,4-methylenedioxybenzylamine (Npip) subunit, a 3-aminopropanic acid (Nce) subunit and a 1-naphthylamine (Na) subunit, and both the peptoid compound and the oligomer have a strong ability to bind to HER2 protein on surfaces of circulating tumor cells (CTCs), and a technology of diagnosing breast cancer on the basis of the peptoid compound can realize non-invasive and label-free rapid diagnosis, in addition, the methods for synthesizing the peptoid compound and the oligomer are simple, the preparation efficiency is high, and the production cost is low.

Abstract: The embodiments disclosed herein provide a peptoid, which is a compound of Formula I or a stereoisomer, a mixture of stereoisomers, or a pharmaceutically acceptable salt thereof. N—R4, N—R3, N—R2, and N—R1 in Formula I are respectively. The peptoid has a strong binding ability with EGFR protein. It can be used not only for targeted treatment of diseases associated with EGFR protein, but also for imaging detection or prognosis monitoring of diseases associated with EGFR protein.

Abstract: The present invention discloses uses of a novel phosphodiesterase 4 (PDE4) inhibitor ZL-n-91 in preparing drugs against lung cancer proliferation and metastasis. The mouse survival curves and in vitro cell experiments show that the PDE4 inhibitor ZL-n-91 can significantly inhibit the proliferation and metastasis of lung cancer cells, indicating that this PDE4 inhibitor ZL-n-91 can become an important target for the studies on anti-lung cancer proliferation and metastasis, to provide a basis for preparing drugs against lung cancer proliferation and metastasis, with promising prospect of development and application.

Abstract: Provided is use of a genetically engineered bacterium of attenuated Salmonella typhimurium for treating liver cancer. The bacterium is attenuated Salmonella typhimurium VNP20009 carrying a plasmid cloned with a methioninase gene. Also provided is a construction method of the bacterium.

Abstract: The present disclosure relates to a peptoid compound, and a derivative, a salt, a preparation method and use thereof. The peptoid compound includes the following subunits: 4-phenylphenethylamine, monoprotected ethylenediamine, monoprotected tetramethylenediamine, 3,4-methylenedioxybenzylamine, isobutylamine, and R(+)-?-methylbenzylamine, in which molecular formulas of the subunits are as follows: in which P is independently an amino protecting group.